| Levi & Korsinsky Urges Viatris Inc. (VTRS) Shareholders to Act Before Lead Plaintiff Deadline June 3, 2025 |
NEW YORK, NY / ACCESS Newswire / May 16, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2?prid=148938&wire=1&utm_campaign=18 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-05-16 18:15:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Reminds Viatris Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 3, 2025 – VTRS |
NEW YORK, May 16, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Viatris Inc. ("Viatris" or the "Company") (NASDAQ: VTRS) of a class action securities lawsuit. |
globenewswire.com |
2025-05-16 17:17:00 |
Czytaj oryginał (ang.) |
| VTRS ALERT: Levi & Korsinsky Files Securities Fraud Class Action Against Viatris Inc. - June 3, 2025 Deadline |
NEW YORK, NY / ACCESS Newswire / May 16, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2?prid=148891&wire=1&utm_campaign=26 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-05-16 13:45:00 |
Czytaj oryginał (ang.) |
| Securities Lawsuit Alert: Viatris Inc. (VTRS) Investors - Contact Levi & Korsinsky Before June 3, 2025 |
NEW YORK, NY / ACCESS Newswire / May 16, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2?prid=148885&wire=1&utm_campaign=2 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-05-16 13:30:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Viatris Inc. of Class Action Lawsuit and Upcoming Deadlines - VTRS |
NEW YORK CITY, NY / ACCESS Newswire / May 16, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Viatris, Inc. ("Viatris" or the "Company") (NASDAQ:VTRS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. |
accessnewswire.com |
2025-05-16 13:00:00 |
Czytaj oryginał (ang.) |
| Lost Money on Viatris Inc. (VTRS)? Urged to Join Class Action Before June 3, 2025 - Contact Levi & Korsinsky |
NEW YORK, NY / ACCESS Newswire / May 16, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2?prid=148807&wire=1&utm_campaign=22 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-05-16 12:00:00 |
Czytaj oryginał (ang.) |
| Did You Lose Money on Viatris Inc. (VTRS)? Levi & Korsinsky Urges Investors to Act Before June 3, 2025 |
NEW YORK, NY / ACCESS Newswire / May 16, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2?prid=148798&wire=1&utm_campaign=28 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-05-16 11:15:00 |
Czytaj oryginał (ang.) |
| VTRS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Viatris Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! |
NEW YORK CITY, NY / ACCESS Newswire / May 16, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Viatris Inc. ("Viatris" or "the Company") (NASDAQ:VTRS) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Viatris securities between August 8, 2024 and February 26, 2025, both dates inclusive (the "Class Period"). |
accessnewswire.com |
2025-05-16 11:00:00 |
Czytaj oryginał (ang.) |
| VTRS Investors Have Opportunity to Lead Viatris Inc. Securities Fraud Lawsuit with the Schall Law Firm |
LOS ANGELES , May 16, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Viatris Inc. ("Viatris" or "the Company") (NASDAQ: VTRS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 8, 2024 and February 26, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before June 3, 2025. |
prnewswire.com |
2025-05-16 10:58:00 |
Czytaj oryginał (ang.) |
| Shareholders that lost money on Viatris Inc.(VTRS) should contact Levi & Korsinsky about pending Class Action - VTRS |
NEW YORK , May 16, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Viatris Inc. ("Viatris" or the "Company") (NASDAQ: VTRS) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Viatris investors who were adversely affected by alleged securities fraud between August 8, 2024 and February 26, 2025. |
prnewswire.com |
2025-05-16 09:45:00 |
Czytaj oryginał (ang.) |
| Shareholders of Viatris Inc. (VTRS): Protect Your Rights Before June 3, 2025 - Contact Levi & Korsinsky |
NEW YORK, NY / ACCESS Newswire / May 15, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2?prid=148769&wire=1&utm_campaign=21 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-05-16 02:30:00 |
Czytaj oryginał (ang.) |
| FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC Continues Lead Plaintiff Search for Viatris Inc. (VTRS) Securities Fraud Class Action |
NEW YORK CITY, NY AND NEW ORLEANS, LA / ACCESS Newswire / May 15, 2025 / Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with losses in excess of $100,000 that they have until June 3, 2025 to file lead plaintiff applications in a securities class action lawsuit against Viatris Inc. ("Viatris" or "the Company") (NasdaqGS:VTRS), if they purchased the Company's securities between August 8, 2024 and February 26, 2025, inclusive (the "Class Period"). |
accessnewswire.com |
2025-05-16 02:15:00 |
Czytaj oryginał (ang.) |
| VTRS ALERT: Levi & Korsinsky Files Securities Fraud Class Action Against Viatris Inc. - June 3, 2025 Deadline |
NEW YORK, NY / ACCESS Newswire / May 15, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2?prid=148736&wire=1&utm_campaign=26 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-05-15 20:00:00 |
Czytaj oryginał (ang.) |
| VTRS CLASS ACTION ALERT: Viatris Inc. Investors are Notified The Company was Sued for Securities Fraud - Contact BFA Law by June 3 |
NEW YORK CITY, NY / ACCESS Newswire / May 15, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Viatris Inc. (NASDAQ:VTRS) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Viatris, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/viatris-inc. |
accessnewswire.com |
2025-05-15 19:33:00 |
Czytaj oryginał (ang.) |
| The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Viatris Lawsuit – VTRS |
NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Viatris Inc. (NASDAQ: VTRS). |
globenewswire.com |
2025-05-15 17:59:00 |
Czytaj oryginał (ang.) |
| Class Action Lawsuit Filed Against Viatris Inc. (VTRS) - Recover Losses - Contact Levi & Korsinsky Before June 3, 2025 |
NEW YORK, NY / ACCESS Newswire / May 15, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2?prid=148707&wire=1&utm_campaign=9 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-05-15 16:15:00 |
Czytaj oryginał (ang.) |
| Securities Lawsuit Alert: Viatris Inc. (VTRS) - Contact Levi & Korsinsky Before June 3, 2025 |
NEW YORK, NY / ACCESS Newswire / May 15, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2?prid=148693&wire=1&utm_campaign=3 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-05-15 15:00:00 |
Czytaj oryginał (ang.) |
| Securities Class Action Lawsuit Filed Against Viatris Inc. (VTRS) - Levi & Korsinsky Represents Shareholders |
NEW YORK, NY / ACCESS Newswire / May 15, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2?prid=148620&wire=1&utm_campaign=13 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-05-15 11:15:00 |
Czytaj oryginał (ang.) |
| VTRS SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Viatris Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! |
NEW YORK CITY, NY / ACCESS Newswire / May 15, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Viatris Inc. ("Viatris" or "the Company") (NASDAQ:VTRS) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Viatris securities between August 8, 2024 and February 26, 2025, both dates inclusive (the "Class Period"). |
accessnewswire.com |
2025-05-15 11:00:00 |
Czytaj oryginał (ang.) |
| Lost Money on Viatris Inc. (VTRS)? Contact Levi & Korsinsky Before June 3, 2025 to Join Class Action |
NEW YORK, NY / ACCESS Newswire / May 15, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2?prid=148605&wire=1&utm_campaign=12 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-05-15 10:30:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viatris Inc. - VTRS |
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Viatris Inc. ("Viatris" or the "Company") (NASDAQ:VTRS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-02-27 22:30:00 |
Czytaj oryginał (ang.) |
| Nxera Pharma Assigns Japan and APAC (ex-China) Rights to Cenerimod for Autoimmune Diseases to Viatris |
Tokyo, Japan and Cambridge, UK, 2 8 February 2025 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) has entered an assignment agreement with Viatris Inc. (“Viatris”), a global healthcare company, and Idorsia Pharmaceuticals Ltd (“Idorsia”), regarding the development and commercialization of cenerimod, a clinical-stage immunology candidate for autoimmune diseases, in Japan, South Korea, and certain countries in the Asia-Pacific (APAC) region (excluding China). The agreement was signed concurrently with Nxera's assignment of its option to these same rights from Idorsia Pharmaceuticals Ltd under its agreement in July 2023 to acquire Idorsia Pharmaceuticals Japan Ltd and Idorsia Pharmaceuticals Korea Co., Ltd. |
globenewswire.com |
2025-02-27 21:05:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Viatris Inc. (VTRS) And Encourages Stockholders to Reach Out |
NEW YORK CITY, NY / ACCESS Newswire / February 27, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Viatris Inc. ("Viatris" or "the Company") (NASDAQ:VTRS). Investors who purchased Viatris securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/VTRS. |
accessnewswire.com |
2025-02-27 20:15:00 |
Czytaj oryginał (ang.) |
| Viatris Q4 Earnings and Revenues Miss Estimates, Stock Plunges |
VTRS Q4 earnings and sales miss estimates. The guidance for 2025 looks disappointing due to the financial impact of the Indore facility warning letter and import alert. |
zacks.com |
2025-02-27 17:01:07 |
Czytaj oryginał (ang.) |
| Viatris Stock Tumbles On Q4 Earnings Miss, FDA Warning Clouds 2025 Outlook |
On Thursday, Viatris Inc. VTRS reported fourth-quarter 2024 sales of $3.52 billion, down 8% year over year, missing the consensus of $3.61 billion. |
benzinga.com |
2025-02-27 15:59:33 |
Czytaj oryginał (ang.) |
| Viatris Inc. (VTRS) Q4 2024 Earnings Call Transcript |
Viatris Inc. (NASDAQ:VTRS ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Bill Szablewski - Head of Capital Markets Scott Smith - CEO Philippe Martin - Chief R&D Officer Doretta Mistras - CFO Corinne Le Goff - Chief Commercial Officer Conference Call Participants David Amsellem - Piper Sandler Ashwani Verma - UBS Chris Schott - JPMorgan Jason Gerberry - Bank of America Umer Raffat - Evercore Balaji Prasad - Barclays Operator Good morning everyone and welcome to the Viatris Q4 and Full Year 2024 Earnings Call. All participants will be in the listen-only mode. |
seekingalpha.com |
2025-02-27 13:51:16 |
Czytaj oryginał (ang.) |
| Viatris: One Swallow Doesn't Make A Summer |
Viatris Inc. missed estimates on sales and earnings per share. The company's 2025 guidance reveals significant challenges, including a $385 million EBITDA hit from issues at the Indore plant. We would stay out of VTRS stock. |
seekingalpha.com |
2025-02-27 12:52:41 |
Czytaj oryginał (ang.) |
| Viatris Misses Estimates, Cash Flow Up |
Viatris (VTRS -16.15%), a global healthcare company known for its broad portfolio of pharmaceutical products, released its fourth-quarter 2024 results on Feb. 27. Despite achieving substantial debt reduction and strategic advancements, Viatris fell short of analysts' forecasts. |
fool.com |
2025-02-27 12:17:03 |
Czytaj oryginał (ang.) |
| Viatris (VTRS) Q4 Earnings and Revenues Lag Estimates |
Viatris (VTRS) came out with quarterly earnings of $0.54 per share, missing the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.61 per share a year ago. |
zacks.com |
2025-02-27 10:55:26 |
Czytaj oryginał (ang.) |
| Drugmaker Viatris forecasts weak 2025 results after import curbs on India plant |
Viatris forecast annual revenue and profit below Wall Street estimates on Thursday, two months after the U.S. health regulator restricted imports from one of the drugmaker's key plants in India. |
reuters.com |
2025-02-27 10:29:33 |
Czytaj oryginał (ang.) |
| Viatris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Financial Guidance |
PITTSBURGH , Feb. 27, 2025 /PRNewswire/ -- Meets 2024 Guidance for Total Revenues, Adjusted EBITDA and Adjusted EPS; Exceeds 2024 Guidance for Free Cash Flow [1] Reports 2024 Total Revenues of $14.7 Billion, U.S. GAAP Net Loss of $(634) Million, Adjusted EBITDA of $4.7 Billion, U.S. GAAP Diluted EPS Loss of $(0.53) per Share, Adjusted EPS of $2.65 per Share, U.S. GAAP Net Cash Provided by Operating Activities of $2.3 Billion, and Free Cash Flow of $2.0 Billion Including ~$650 Million of Transaction-Related Costs Delivers Strong New Product Revenues of $582 Million in 2024 Returns $825 Million in Capital to Shareholders and Repays $3.7 Billion of Debt in 2024 Announces Plan to Prioritize Capital Return in 2025, Including $500 Million to $650 Million in Share Repurchases Expects Six Phase 3 Data Readouts and Achievement of Important Late-Stage Development Milestones for Innovative Assets Selatogrel, Cenerimod and Sotagliflozin in 2025 Provides 2025 Financial Guidance Including the Expected Financial Impact From Indore Facility Warning Letter and Import Alert Begins Enterprise-Wide Initiative to Review its Global Infrastructure and Identify Additional Cost Savings Viatris Inc. (Nasdaq: VTRS) today announced strong financial results for the fourth quarter and full year 2024—including divestiture-adjusted operational revenue growth of 2% for the full year with growth across all segments, new product revenues of $582 million and full year free cash flow that exceeded the Company's guidance.[2] "2024 was a good year for Viatris with full year operational revenue growth of 2%, excluding divestitures, in line with our guidance," said Scott A. |
prnewswire.com |
2025-02-27 08:45:00 |
Czytaj oryginał (ang.) |
| Viatris Maintains Dividend Policy for 2025 and Announces Quarterly Dividend |
PITTSBURGH , Feb. 27, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced that on February 24, 2025, its Board of Directors approved a 2025 dividend policy of 48 cents ($0.48) per share and declared a quarterly dividend of 12 cents ($0.12) for each issued and outstanding share of the Company's common stock. The dividend is payable on March 18, 2025, to shareholders of record at the close of business on March 10, 2025. |
prnewswire.com |
2025-02-27 08:30:00 |
Czytaj oryginał (ang.) |
| Idorsia and Viatris update their collaboration for selatogrel and cenerimod |
Ad hoc announcement pursuant to Art. 53 LR Idorsia's contribution to the development costs reduced by USD 100 million Viatris potential regulatory and sales milestones payments to Idorsia reduced by USD 250 million Allschwil, Switzerland – February 26, 2025 Idorsia Ltd (SIX: IDIA) today announced that it has reached an agreement with Viatris Inc. (NASDAQ: VTRS) to update the terms of the global development and commercialization collaboration for selatogrel and cenerimod. |
globenewswire.com |
2025-02-26 02:55:00 |
Czytaj oryginał (ang.) |
| What's in Store for These 5 Biotech Stocks This Earnings Season? |
Let's look at five biotech and drug companies, VTRS, PRGO, NVAX, NTLA and IOVA, slated to release their fourth-quarter 2024 results on Feb. 27, 2025. |
zacks.com |
2025-02-24 13:30:24 |
Czytaj oryginał (ang.) |
| Stay Ahead of the Game With Viatris (VTRS) Q4 Earnings: Wall Street's Insights on Key Metrics |
Beyond analysts' top -and-bottom-line estimates for Viatris (VTRS), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024. |
zacks.com |
2025-02-24 12:22:12 |
Czytaj oryginał (ang.) |
| What's in the Cards for Viatris Stock This Q4 Earnings? |
VTRS' Q4 results are likely to gain from new product launches in all major geographies. |
zacks.com |
2025-02-21 16:55:35 |
Czytaj oryginał (ang.) |
| Earnings Preview: Viatris (VTRS) Q4 Earnings Expected to Decline |
Viatris (VTRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-02-20 13:06:12 |
Czytaj oryginał (ang.) |
| Viatris to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025 |
PITTSBURGH , Feb. 3, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) will report financial results for the fourth quarter and full year 2024 on Thursday, February 27, 2025. Company executives will host a webcast at 8:30 a.m. |
prnewswire.com |
2025-02-03 18:30:00 |
Czytaj oryginał (ang.) |
| Viatris: Consolidate In 2025, Win In 2026 - How 'Phase 2' Of Business Plan May Play Out |
Viatris, formed from Mylan and Pfizer's Established Brands, has faced stock price volatility since its inception in 2020. I rated Viatris a "Buy" last October, based on management's completion of "Phase 1" of its business transformation, and initiation of "Phase 2" of their strategic plan — returning to growth. Viatris markets a mix of generic and established brand drugs, with the latter's revenues declining due to patent expiries and market competition. |
seekingalpha.com |
2025-01-24 19:25:29 |
Czytaj oryginał (ang.) |
| Is Viatris (VTRS) a Great Value Stock Right Now? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2025-01-15 12:46:22 |
Czytaj oryginał (ang.) |
| US FDA sends warning letter to Viatris over India manufacturing facility |
Viatris said on Monday it has received a warning letter from the U.S. Food and Drug Administration after an inspection at its oral finished dose manufacturing facility in Indore, India earlier this year. |
reuters.com |
2024-12-23 10:12:17 |
Czytaj oryginał (ang.) |
| Viatris Announces Publication of Phase 2b CARE Study Data for Cenerimod in Lancet Rheumatology |
Biomarker data from CARE study characterizing cenerimod's mechanism of action in systemic lupus erythematosus also published in the Annals of the Rheumatic Diseases PITTSBURGH , Dec. 18, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced the publication of Phase 2b CARE study results evaluating the efficacy and safety of cenerimod in adults with moderate-to-severe systemic lupus erythematosus (SLE). The results, published in Lancet Rheumatologyi , showed cenerimod 4 mg demonstrated clinically meaningful and sustained improvement from baseline on multiple measures of SLE disease activity compared to placebo, in addition to stable background SLE therapy. |
prnewswire.com |
2024-12-18 08:59:00 |
Czytaj oryginał (ang.) |
| Mapi Pharma is Seeking New Depot Product Partnerships |
Management to Participate in 7th Annual Evercore HealthCONx Conference Management to Participate in 7th Annual Evercore HealthCONx Conference |
globenewswire.com |
2024-12-02 10:30:00 |
Czytaj oryginał (ang.) |
| 2 Generic Drug Stocks Ready to Surge in 2025 |
Generic and biosimilar drugs are often preferred over the brand name version due to their cheaper prices. Generics are exact duplicates of the branded counterparts, while biosimilars are "similar" and often require clinical trials. |
marketbeat.com |
2024-11-27 10:30:26 |
Czytaj oryginał (ang.) |
| UK watchdog fines Viatris $1.9 mln over rule breach in Theramex probe |
Britain's competition watchdog fined U.S. firm Viatris 1.5 million pounds ($1.88 million) on Friday for violating an order during its investigation into Theramex's acquisition of European rights to two of Viatris's women's healthcare product ranges. |
reuters.com |
2024-11-22 07:01:51 |
Czytaj oryginał (ang.) |
| Viatris Inc. (VTRS) Management Presents at Jefferies London Healthcare Conference (Transcript) |
Viatris Inc. (NASDAQ:VTRS ) Jefferies London Healthcare Conference Transcript November 21, 2024 5:30 AM ET Company Participants Scott Smith - Chief Executive Officer Doretta Mistras - Chief Financial Officer Corinne Le Goff - Chief Commercial Officer Philippe Martin - Chief R&D Officer Conference Call Participants Glen Santangelo - Jefferies Glen Santangelo All right. Good morning, everybody. |
seekingalpha.com |
2024-11-21 10:59:45 |
Czytaj oryginał (ang.) |
| Viatris Inc. (VTRS) UBS Global Healthcare Conference (Transcript) |
Viatris Inc. (NASDAQ:VTRS ) UBS Global Healthcare Conference November 12, 2024 11:45 AM ET Company Participants Doretta Mistras - CFO Conference Call Participants Ashwani Verma - UBS Ashwani Verma Good day, everybody. My name is Ash Verma, I cover SMID-cap, biotech and spec pharma at UBS, and welcome to UBS Global Healthcare Conference with us. |
seekingalpha.com |
2024-11-15 17:21:04 |
Czytaj oryginał (ang.) |
| Bargain Priced Viatris Reports Strong Q3 Earnings Results |
Bargain Priced Viatris Reports Strong Q3 Earnings Results |
seekingalpha.com |
2024-11-08 16:36:46 |
Czytaj oryginał (ang.) |
| Generic Drugmaker Viatris Beats Expectations In Q3, CEO Praises $2 Billion Debt Paydown |
Viatris Inc. VTRS reported third-quarter 2024 total net sales of $3.74 billion. That's down 5%, beating the consensus of $3.71 billion, but up about 3% on a divestiture-adjusted operational basis compared to third-quarter 2023 results. |
benzinga.com |
2024-11-07 14:39:30 |
Czytaj oryginał (ang.) |
| Viatris Beats on Q3 Earnings and Revenues, Lowers Profit Guidance |
VTRS Q3 earnings and sales beat estimates. New products perform well. |
zacks.com |
2024-11-07 14:20:20 |
Czytaj oryginał (ang.) |
| Viatris Inc. (VTRS) Q3 2024 Earnings Call Transcript |
Viatris Inc. (NASDAQ:VTRS ) Q3 2024 Earnings Conference Call November 6, 2024 8:30 AM ET Company Participants Bill Szablewski - Head of Capital Markets Scott Smith - CEO Philippe Martin - Chief R&D Officer Doretta Mistras - CFO Corinne Le Goff - Chief Commercial Officer Conference Call Participants Glen Santangelo - Jefferies Jason Gerberry - Bank of America Ethan Brown - JPMorgan Ashwani Verma - UBS David Amsellem - Piper Sandler Balaji Prasad - Barclays Operator Good morning, everyone, and welcome to the Viatris Q3 2024 Earnings Call. All participants will be in a listen-only mode. |
seekingalpha.com |
2024-11-07 12:50:55 |
Czytaj oryginał (ang.) |
| Viatris (VTRS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates |
While the top- and bottom-line numbers for Viatris (VTRS) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
zacks.com |
2024-11-07 12:35:38 |
Czytaj oryginał (ang.) |
| Viatris (VTRS) Beats Q3 Earnings and Revenue Estimates |
Viatris (VTRS) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.68 per share. This compares to earnings of $0.78 per share a year ago. |
zacks.com |
2024-11-07 11:30:30 |
Czytaj oryginał (ang.) |
| Xanax maker Viatris beats quarterly estimates on demand for new generic drugs |
Drugmaker Viatris beat Wall Street estimates for third-quarter profit and revenue on Thursday, helped by strong demand for its new generic asthma and ADHD drugs, among others, sending its shares up 2.5% premarket. |
reuters.com |
2024-11-07 10:57:57 |
Czytaj oryginał (ang.) |
| What's in Store for These 5 Drug & Biotech Stocks in Q3 Earnings? |
Let us look at five large biotech and generic drug companies, NVO, GILD, MRNA, VTRS and TEVA, which are gearing up for their earnings releases this week. |
zacks.com |
2024-11-05 18:00:20 |
Czytaj oryginał (ang.) |
| Viatris Announces Third Quarter 2024 Dividend |
PITTSBURGH , Nov. 5, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced that on November 4, 2024, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding share of the Company's common stock. The dividend is payable on December 13, 2024, to shareholders of record as of the close of business on November 22, 2024. |
prnewswire.com |
2024-11-05 08:59:00 |
Czytaj oryginał (ang.) |
| Unveiling Viatris (VTRS) Q3 Outlook: Wall Street Estimates for Key Metrics |
Besides Wall Street's top -and-bottom-line estimates for Viatris (VTRS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024. |
zacks.com |
2024-11-04 12:22:13 |
Czytaj oryginał (ang.) |
| Viatris Named to Forbes' World's Top Companies for Women 2024 List |
PITTSBURGH , Oct. 29, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that it has been named to Forbes' World's Top Companies for Women 2024 List. This award is presented in collaboration with Statista, the world-leading statistics portal and industry ranking provider. |
prnewswire.com |
2024-10-29 14:00:00 |
Czytaj oryginał (ang.) |
| Viatris to Participate in the UBS Global Healthcare Conference and Jefferies London Healthcare Conference |
PITTSBURGH , Oct. 29, 2024 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the company will participate in two upcoming healthcare conferences. Details of the presentations can be found below: UBS Global Healthcare Conference Date: Tuesday, November 12, 2024 Time: 8:45 a.m. |
prnewswire.com |
2024-10-29 11:00:00 |
Czytaj oryginał (ang.) |
| Idorsia announces financial results for the first nine months of 2024 |
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – October 29, 2024 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first nine months of 2024. |
globenewswire.com |
2024-10-29 04:00:00 |
Czytaj oryginał (ang.) |